Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Complete Nutrition launches new intra-workout drink
The supplement is designed to hydrate,energize and aid athletes more effectively than sports drinks or water and to provide essential nutrients. 3Plenish meets both the intra- and post-workout
The supplement is designed to hydrate,energize and aid athletes more effectively than sports drinks or water and to provide essential nutrients. 3Plenish meets both the intra- and post-workout
The Switching boosted PI to Rilpivirine In Combination with Truvada as a Single Tablet Regimen (SPIRIT) trial identified that once-daily single tablet regimen Complera maintains HIV suppression among
Oxacillin for Injection, USP, is a semisynthetic penicillin indicated in the treatment of infections caused by penicillinase producing staphylococci which have demonstrated susceptibility to the drug. The US
Abilify ODT, which utilizes Catalent’s Zydis fast dissolve drug delivery technology, is designed to improve manic symptoms associated with bipolar disorder as well as to treat schizophrenia. Catalent
The collaboration aims at developing new class of ADHD treatments which demonstrate increased efficacy due to higher affinity for the target receptor, in addition to improved safety due
Under the agreement, Suzhou will use anti-inflammatory compounds and the method to develop small molecule compounds to treat allergic rhinitis and atopic dermatitis. Financial terms and molecular targets
Bilastine is an anti-histamine product, designed for the treatment of symptoms of allergic rhinoconjunctivitis and urticaria. Under the agreement, Faes Farma will receive an initial payment of €10m,
The PAREXEL BioPharm Unit provides the defined expertise, global infrastructure, operational excellence and technologies needed to help small biopharmaceutical companies advance their drugs through the development cycle. The
The double-blind, placebo-controlled trial is designed to evaluate the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee.
The rapid fire test, which was conducted at Medicago’s facility in Durham, North Carolina, is the fifth milestone under a technology investment agreement with DARPA to demonstrate the